Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 07/05/2018
Entire Document
 


Case 18-10518-KG    Doc 446    Filed 06/29/18    Page 8 of 11

 

In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: May 1, 2018 - May 31, 2018

 

MOR - 2

Statement of Operations

For the Period: May 1, 2018 - May 31, 2018

(Unaudited)

 

$ USD ‘000s

   May 1, 2018 - May 31, 2018     March 12 - May 31 2018  

Net product sales

   $ 7,895     $ 20,162  

Cost of product sales

     (1,728     (4,465

Operating expenses:

    

Research and development

     (636     (1,813

Selling, general and administrative

     (8,842     (24,645

Amortization expense of intangible assets

     (661     (1,750
  

 

 

   

 

 

 

Total operating expenses

     (10,139     (28,208
  

 

 

   

 

 

 

Loss from operations

     (3,972     (12,511

Other income/(expense):

    

Interest income

     148       394  

Refundable tax credit(2)

     —         1,300  

Interest expense

     (147     (453
  

 

 

   

 

 

 

Total other income (expenses)

     1       1,241  
  

 

 

   

 

 

 

Net loss

     (3,972     (11,269

Reorganization expenses(1)

     (3,800     (174,539
  

 

 

   

 

 

 

Net loss

   $ (7,772   $ (185,808
  

 

 

   

 

 

 

Notes:

 

(1) Reorganization expenses includes the write up of the notes to the principle balance and the elimination of the debt discount and debt costs related to the 2013 debt.
(2) Refundable tax credit includes refundable alternative minimum tax as created by the Tax Cuts and Jobs Act.